2013-02-21 07:03:44 -

BB BIOTECH AG /
Publication of the annual report 2012 of BB Biotech AG
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement. 

Today BB Biotech AG is publishing its annual report for the past fiscal year.


For further information:
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Dr. Silvia Schanz, tel +41 44 267 72 66, ssc@bellevue.ch
Claude Mikkelsen, tel +41 44 267 67 26, cmi@bellevue.ch
www.bbbiotech.com


Company profile
BB Biotech invests in companies in the fast growing market of biotechnology and
is one of the world's largest investors in this sector with CHF 1.3 billion in
assets under management. BB Biotech is listed in Switzerland, Germany and Italy.
Its investments are focused on listed companies that are developing and
commercializing novel   medical treatments and cures. BB Biotech's investment
selection process is guided by the fundamental research and analysis of
physicians and molecular biologists. Its Board of Directors has many years of
experience in industry and science. 

Annual report 2012 (PDF): 
 hugin.info/130285/R/1679776/548628.pdf



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: BB BIOTECH AG via Thomson Reuters ONE
[HUG#1679776]